Lexaria Updates Its Ongoing Human Study GLP-1-H24-4

About this update from Lexaria Bioscience Corp.

[{"type":"text","content":"Registered Phase-1b 12-week Study Investigating Safety, Diabetes Control, and Weight Loss\nKELOWNA, BRITISH COLUMBIA - April 3, 2025 (NEWMEDIAWIRE) - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the \"Study\") underway in Australia.\nEnrollment of patients for all 5 Study arms has now been completed on schedule. Participation interest in the Study was extremely high, so the Study overenrolled entering a total of 24 patients per Study arm versus the original target of 20. Completion of enrollment signifies the important \"last patient in\" (\"LPI\") clinical study milestone, meaning that treatment of all patients is expected to be completed roughly twelve weeks from now, to be followed by the series of patient sample analyses, data compilation, analysis and reporting.\n\"Lexaria is pleased to have reached LPI enrollment completion,\" said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience Corp. \"Dosing is progressing nicely and, at this point, we are expecting the Study to complete on schedule.\"\nAbout The Study\nThe Study is underway with 24 overweight, obese, pre- or type 2 diabetic patients for each of the 5 Study Arms, four of which are evaluating DehydraTECH-semaglutide, DehydraTECH-tirzepatide, and DehydraTECH-cannabidiol (\"CBD\"), with Study Arm 4 being the control arm. All drugs are being administered daily by oral tablet or capsule - there are no drug injections involved in this Study as Lexaria is promoting a change in the standard of care, moving away from injections and instead embracing oral DehydraTECH delivery.\nArm 1 of the Study is utilizing a proprietary, patented DehydraTECH-CBD formulation. Our 2022 diabetes animal study DIAB-A22-1, utilizing DehydraTECH-CBD evidenced weight loss of 7% and reduced blood glucose levels of 19.9%+/-7% (p","length":2745,"tagName":"div"}]

More updates from Lexaria Bioscience Corp.